CD47 and neoplasm: In GBM, preclinical data indicate that blocking the CD47-SIRPα axis can induce antitumor effects (13, 14, 57), although a combination with chemotherapy may be required to activate ER stress responses that promote tumor cell phagocytosis by professional antigen presenting cells (14).